CatalYm today announced treatment of the first patients in a series of phase 2a cohorts targeting solid tumors, initiating phase 2 development of CTL-002. The trial will evaluate the safety and efficacy of the company’s lead product candidate, the GDF-15 neutralizing antibody CTL-002 (visugromab), at the confirmed target dose in five cohorts in combination with nivolumab in […]
continue readingCatalYm Presents Expanded Clinical and New Preclinical Data from GDF-15-targeting Program CTL-002 at SITC Conference
First four dose escalation levels completed showing excellent tolerability for CTL-002 as monotherapy and in combination with PD-1 Preliminary pharmacodynamic analyses at early dose levels indicate CTL-002-mediated selective T cell shift into the tumor microenvironment Preclinical in vivo study validates relevance of GDF-15 as an exciting novel immuno-oncology target CatalYm today announced the presentation of […]
continue reading